Philip Szekeres
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Philip Szekeres has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Carmela Ciardullo
Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK
10 shared publications - Giulia Fabbri
AstraZeneca, Waltham, Massachusetts
10 shared publications - Lauren Averett Byers
Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
10 shared publications - Luis Tobalina
Faculty of Medicine, Joint Research Centre for Computational Biomedicine (JRC-COMBINE), RWTH Aachen University
10 shared publications - Silvija Kraljevic
AstraZeneca, Cambridge, United Kingdom
10 shared publications - Thomas Hedley Carr
AstraZeneca, Cambridge, United Kingdom
10 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 4 shows the longitudinal ctDNA dynamics of all patients on study.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 4 shows the longitudinal ctDNA dynamics of all patients on study.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 1 shows genome-wide patterns of somatic copy number variation based on baseline plasma ctDNA from n = 27 patients.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 1 shows genome-wide patterns of somatic copy number variation based on baseline plasma ctDNA from n = 27 patients.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Table 1 shows PIK3CA and PTEN alterations in baseline ctDNA samples, with associated mutation type, amino acid change, allele frequency, OncoKB classification, SIFT/PolyPhen predictions, and affected protein domain.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Table 1 shows PIK3CA and PTEN alterations in baseline ctDNA samples, with associated mutation type, amino acid change, allele frequency, OncoKB classification, SIFT/PolyPhen predictions, and affected protein domain.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 6 shows the clonal hematopoiesis mutation profiles and their influence on molecular response.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 6 shows the clonal hematopoiesis mutation profiles and their influence on molecular response.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 3 shows the relationship of baseline cfDNA levels and maximum and mean VAF to sum of target lesions, ECOG performance status, presence of liver or lung metastases, and treatment duration.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 3 shows the relationship of baseline cfDNA levels and maximum and mean VAF to sum of target lesions, ECOG performance status, presence of liver or lung metastases, and treatment duration.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Purpose:Small cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis despite initial treatment responses. This study evaluates ctDNA for monitoring disease and assessing the efficacy of first-line therapy in patients with extensive-stage SCLC (1L ES-SCLC).Experimental Design:In the TAZMAN trial, 31 patients with 1L ES-SCLC received standard treatment with durvalumab and etoposide plus carboplatin or cisplatin. We analyzed 228 plasma samples from 27 of 31 patients using a liquid biopsy approach to detect somatic mutations and copy-number aberrations, while also accounting for clonal hematopoiesis mutations.Results:Baseline ctDNA analysis detected somatic alterations in 96.3% of patients, primarily in genes like TP53 and RB1. ctDNA dynamics during early treatment showed significant reductions in variant allele frequency, confirming early but short-lived chemosensitivity. Reduction of ctDNA below the limit of detection of the assay during induction predicted patients with longer treatment duration, surpassing imaging in distinguishing these patients. ctDNA changes often anticipated disease relapse before conventional imaging, suggesting ctDNA as a more sensitive treatment efficacy marker.Conclusions:The study shows that early ctDNA dynamics can provide valuable insights into treatment efficacy and potential molecular relapse in 1L ES-SCLC. ctDNA can enhance treatment monitoring and potentially guide the discontinuation of ineffective therapies. Larger studies with extended next-generation sequencing panels are needed to fully understand the potential of ctDNA in SCLC management from diagnosis to treatment and recurrence surveillance.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Purpose:Small cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis despite initial treatment responses. This study evaluates ctDNA for monitoring disease and assessing the efficacy of first-line therapy in patients with extensive-stage SCLC (1L ES-SCLC).Experimental Design:In the TAZMAN trial, 31 patients with 1L ES-SCLC received standard treatment with durvalumab and etoposide plus carboplatin or cisplatin. We analyzed 228 plasma samples from 27 of 31 patients using a liquid biopsy approach to detect somatic mutations and copy-number aberrations, while also accounting for clonal hematopoiesis mutations.Results:Baseline ctDNA analysis detected somatic alterations in 96.3% of patients, primarily in genes like TP53 and RB1. ctDNA dynamics during early treatment showed significant reductions in variant allele frequency, confirming early but short-lived chemosensitivity. Reduction of ctDNA below the limit of detection of the assay during induction predicted patients with longer treatment duration, surpassing imaging in distinguishing these patients. ctDNA changes often anticipated disease relapse before conventional imaging, suggesting ctDNA as a more sensitive treatment efficacy marker.Conclusions:The study shows that early ctDNA dynamics can provide valuable insights into treatment efficacy and potential molecular relapse in 1L ES-SCLC. ctDNA can enhance treatment monitoring and potentially guide the discontinuation of ineffective therapies. Larger studies with extended next-generation sequencing panels are needed to fully understand the potential of ctDNA in SCLC management from diagnosis to treatment and recurrence surveillance.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 7 shows RECIST and ctDNA longitudinal assessment in the patient showing evidence of a newly acquired NOTCH3 variant on treatment.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 7 shows RECIST and ctDNA longitudinal assessment in the patient showing evidence of a newly acquired NOTCH3 variant on treatment.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 2 shows a density histogram of n = 27 baseline plasma ctDNA samples with copy number (log2 ratio) indicated on the x-axis and counts/density on the y-axis.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 2 shows a density histogram of n = 27 baseline plasma ctDNA samples with copy number (log2 ratio) indicated on the x-axis and counts/density on the y-axis.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 5 shows the RECIST and ctDNA longitudinal assessment in four representative patients.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Supplementary Figure 5 shows the RECIST and ctDNA longitudinal assessment in four representative patients.
- 11 August 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (21) , 4457-4462
Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Purpose: Small cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis despite initial treatment responses. This study evaluates ctDNA for monitoring disease and assessing the efficacy of first-line therapy in patients with extensive-stage SCLC (1L ES-SCLC). Experimental Design: In the TAZMAN trial, 31 patients with 1L ES-SCLC received standard treatment with durvalumab and etoposide plus carboplatin or cisplatin. We analyzed 228 plasma samples from 27 of 31 patients using a liquid biopsy approach to detect somatic mutations and copy-number aberrations, while also accounting for clonal hematopoiesis mutations. Results: Baseline ctDNA analysis detected somatic alterations in 96.3% of patients, primarily in genes like TP53 and RB1. ctDNA dynamics during early treatment showed significant reductions in variant allele frequency, confirming early but short-lived chemosensitivity. Reduction of ctDNA below the limit of detection of the assay during induction predicted patients with longer treatment duration, surpassing imaging in distinguishing these patients. ctDNA changes often anticipated disease relapse before conventional imaging, suggesting ctDNA as a more sensitive treatment efficacy marker. Conclusions: The study shows that early ctDNA dynamics can provide valuable insights into treatment efficacy and potential molecular relapse in 1L ES-SCLC. ctDNA can enhance treatment monitoring and potentially guide the discontinuation of ineffective therapies. Larger studies with extended next-generation sequencing panels are needed to fully understand the potential of ctDNA in SCLC management from diagnosis to treatment and recurrence surveillance.
- 11 August 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (21) , 4457-4462
Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Purpose: Small cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis despite initial treatment responses. This study evaluates ctDNA for monitoring disease and assessing the efficacy of first-line therapy in patients with extensive-stage SCLC (1L ES-SCLC). Experimental Design: In the TAZMAN trial, 31 patients with 1L ES-SCLC received standard treatment with durvalumab and etoposide plus carboplatin or cisplatin. We analyzed 228 plasma samples from 27 of 31 patients using a liquid biopsy approach to detect somatic mutations and copy-number aberrations, while also accounting for clonal hematopoiesis mutations. Results: Baseline ctDNA analysis detected somatic alterations in 96.3% of patients, primarily in genes like TP53 and RB1. ctDNA dynamics during early treatment showed significant reductions in variant allele frequency, confirming early but short-lived chemosensitivity. Reduction of ctDNA below the limit of detection of the assay during induction predicted patients with longer treatment duration, surpassing imaging in distinguishing these patients. ctDNA changes often anticipated disease relapse before conventional imaging, suggesting ctDNA as a more sensitive treatment efficacy marker. Conclusions: The study shows that early ctDNA dynamics can provide valuable insights into treatment efficacy and potential molecular relapse in 1L ES-SCLC. ctDNA can enhance treatment monitoring and potentially guide the discontinuation of ineffective therapies. Larger studies with extended next-generation sequencing panels are needed to fully understand the potential of ctDNA in SCLC management from diagnosis to treatment and recurrence surveillance.